Respiratory

Respiratory drugs and is a growing sector of the pharmaceuticals industry, and we have all the information resources that you need to be a leading player in this lucrative market. The publications listed under Research and Markets’ Respiratory category cover all drugs and therapeutics for conditions and diseases relating to the lungs and/or breathing, such as Acute Respiratory Distress Syndrome (ARDS), allergy, asthma, bronchitis, COPD (chronic obstructive pulmonary disease), cystic fibrosis, emphysema, lung disease, pneumonia, sinus infections, sleep apnea and others.

Our reports, books, and subscriptions will provide you with the latest industry news, forecasts, market trends and company profiles of market leaders and niche players including: Accentia Biopharmaceuticals, Aerogen, Aerovance, airPharma, AstraZeneca, Aventis Pharma, Bespak, Boehringer Ingelheim Pharmaceuticals, Cadila Pharmaceuticals, Dr. Reddys Laboratories, EvoGenix, GlaxoSmithKlineInyx, The Merck Generics Group, Novartis AG, Pfizer, Ranbaxy Laboratories, Respironics, Sandoz International, Schering-Plough, etc.

Publications on smoking cessation are listed under the OTC sub-category in the Pharmaceuticals section. Show Less ... more

• Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Nov 2012 , Pages: 127
  Respiratory Tract Inflammatory Disorders – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012', provides an overview of...

• Allergic Asthma - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Nov 2012 , Pages: 85
  Allergic Asthma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Allergic Asthma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report...

• Pulmonary Fibrosis - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Nov 2012 , Pages: 175
  Pulmonary Fibrosis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Pulmonary Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

• Bronchitis Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Nov 2012 , Pages: 123
  Bronchitis Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Bronchitis Global Clinical Trials Review, H2, 2012" provides data on the Bronchitis clinical trial scenario....

• Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Nov 2012 , Pages: 180
  Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review,...

• Diphtheria Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Nov 2012 , Pages: 90
  Diphtheria Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Diphtheria Global Clinical Trials Review, H2, 2012" provides data on the Diphtheria clinical trial scenario....

• Allergic Rhinitis Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Nov 2012 , Pages: 119
  Allergic Rhinitis Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Allergic Rhinitis Global Clinical Trials Review, H2, 2012" provides data on the Allergic Rhinitis clinical...

• Bronchopulmonary Dysplasia - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 53
  Bronchopulmonary Dysplasia – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Bronchopulmonary Dysplasia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic...

• Lung Injury - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 95
  Lung Injury – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Lung Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Cystic Fibrosis - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 212
  Cystic Fibrosis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report...

• Diphtheria - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 70
  Diphtheria – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Diphtheria - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Bronchiolitis - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Oct 2012 , Pages: 58
  Bronchiolitis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Bronchiolitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Acute Lung Injury Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Oct 2012 , Pages: 91
  Acute Lung Injury Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Acute Lung Injury Global Clinical Trials Review, H2, 2012" provides data on the Acute Lung Injury clinical...

• Respiratory Insufficiency Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Oct 2012 , Pages: 75
  Respiratory Insufficiency Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Respiratory Insufficiency Global Clinical Trials Review, H2, 2012" provides data on the Respiratory...

• Emphysema Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Oct 2012 , Pages: 108
  Emphysema Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Emphysema Global Clinical Trials Review, H2, 2012" provides data on the Emphysema clinical trial scenario. This...

• Strategic Analysis of the North American Respiratory Protection Market 2012

  EURO€ 4,612.00USD$ 6,000.00GBP£ 3,880.00AUD$ 5,868.00JPY¥ 592,398.00SEK 39 395,00CHF 5'655.00CAD$ 6,114.00 Frost & Sullivan, Oct 2012 , Pages: 161
  Strategic Analysis of the North American Respiratory Protection Market 2012 - The Search for a New Growth Pipeline This study provides a 360-degree perspective on the 2011 North American market for...

• Global Markets For Patient Monitoring Technologies In 2012

  EURO€ 4,608.00USD$ 5,995.00GBP£ 3,877.00AUD$ 5,864.00JPY¥ 591,904.00SEK 39 362,00CHF 5'650.00CAD$ 6,109.00 Life Science Intelligence, Oct 2012
  Patient monitoring products are used across multiple care settings to gather and track physiological information These devices are either highly specialized, tracking just a single parameter, or they...

• Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Sep 2012 , Pages: 66
  Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012" provides...

• Perennial Allergic Rhinitis - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 48
  Perennial Allergic Rhinitis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Perennial Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic...

• Lung Disease - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 58
  Lung Disease – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Lung Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Bronchiectasis - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 71
  Bronchiectasis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Bronchiectasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 60
  Acute Respiratory Distress Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s...

• Apnea - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 66
  Apnea – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Apnea - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Cough - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 69
  Cough – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Cough - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Respiratory Depression - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 37
  Respiratory Depression – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Respiratory Depression - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline....

• Asthma - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Sep 2012 , Pages: 281
  Asthma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2012', provides an overview of the indication’s...

• 09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 153.00USD$ 199.00GBP£ 129.00AUD$ 195.00JPY¥ 19,648.00SEK 1 307,00CHF 188.00CAD$ 203.00 Life Science Intelligence, Sep 2012
  This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...

• Future Horizons in the Global Respiratory Disease Market

  EURO€ 7,072.00USD$ 9,200.00GBP£ 5,950.00AUD$ 8,998.00JPY¥ 908,343.00SEK 60 406,00CHF 8'671.00CAD$ 9,375.00 Venture Planning Group (VPG), Aug 2012
  This report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan Current scientific views on epidemiology and etiology are provided...

• Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Aug 2012 , Pages: 68
  Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012 Summary Our clinical trial report, “Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012" provides...

• Sleep Apnea - Pipeline Review, H2 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2012 , Pages: 67
  Sleep Apnea – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Sleep Apnea - Pipeline Review, H2 2012', provides an overview of the Sleep Apnea therapeutic pipeline. This report provides...

• Respiratory Distress Syndrome - Pipeline Review, H2 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2012 , Pages: 81
  Respiratory Distress Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Respiratory Distress Syndrome - Pipeline Review, H2 2012', provides an overview of the Respiratory Distress...

• Acute Lung Injury - Pipeline Review, H2 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2012 , Pages: 82
  Acute Lung Injury – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Acute Lung Injury - Pipeline Review, H2 2012', provides an overview of the Acute Lung Injury therapeutic pipeline. This...

• Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers

  EURO€ 4,381.00USD$ 5,700.00GBP£ 3,686.00AUD$ 5,575.00JPY¥ 562,778.00SEK 37 425,00CHF 5'372.00CAD$ 5,808.00 Datamonitor, Jul 2012 , Pages: 42
  Overview of asthma disease definition and a review of epidemiology literature This report provides in-depth analysis of patient populations, a 10-year case forecast, and key patient segments across...

• Asthma Global Clinical Trials Review, H1, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Jun 2012 , Pages: 163
  Asthma Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Asthma Global Clinical Trials Review, H1, 2012" provides data on the Asthma clinical trial scenario. This...

• Sleep Apnea Global Clinical Trials Review, H1, 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Jun 2012 , Pages: 119
  Sleep Apnea Global Clinical Trials Review, H1, 2012 Summary Our clinical trial report, “Sleep Apnea Global Clinical Trials Review, H1, 2012" provides data on the Sleep Apnea clinical trial scenario....

• Lymphangioleiomyomatosis - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 31
  Lymphangioleiomyomatosis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Lymphangioleiomyomatosis - Pipeline Review, H1 2012', provides an overview of the Lymphangioleiomyomatosis therapeutic...

• Neonatal Respiratory Distress Syndrome - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 38
  Neonatal Respiratory Distress Syndrome – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Neonatal Respiratory Distress Syndrome - Pipeline Review, H1 2012', provides an overview of the...

• Malignant Pleural Effusion - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 31
  Malignant Pleural Effusion – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Malignant Pleural Effusion - Pipeline Review, H1 2012', provides an overview of the Malignant Pleural Effusion...

• Dyspnea - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 27
  Dyspnea – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Dyspnea - Pipeline Review, H1 2012', provides an overview of the Dyspnea therapeutic pipeline. This report provides information...

• Seasonal Allergic Rhinitis - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 70
  Seasonal Allergic Rhinitis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Seasonal Allergic Rhinitis - Pipeline Review, H1 2012', provides an overview of the Seasonal Allergic Rhinitis...

• Obstructive Sleep Apnea - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jun 2012 , Pages: 54
  Obstructive Sleep Apnea – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Obstructive Sleep Apnea - Pipeline Review, H1 2012', provides an overview of the Obstructive Sleep Apnea therapeutic...

• Epidemiology: Asthma in China – Aging population and rising urbanization increase asthma prevalence

  EURO€ 5,842.00USD$ 7,600.00GBP£ 4,915.00AUD$ 7,433.00JPY¥ 750,371.00SEK 49 900,00CHF 7'163.00CAD$ 7,744.00 Datamonitor, Jun 2012 , Pages: 36
  Overview of asthma prevalence in China and a review of epidemiology literature This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments...

• Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Jun 2012 , Pages: 194
  Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles Summary GBI Research in its report “Endpoints...

• Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Jun 2012 , Pages: 74
  Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Acute...

• Product Profiles: Asthma – Key Companies Act to Maintain Dominance

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Jun 2012 , Pages: 144
  Asthma is a well established market, but key unmet needs continue to drive development While Advair (fluticasone/salmeterol) has market dominance, GlaxoSmithKline is racing to bring a once-daily follow-on...

• 06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jun 2012 , Pages: 40
  This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...

• Bronchiectasis Global Clinical Trials Review, H1, 2012

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, May 2012 , Pages: 116
  Bronchiectasis Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchiectasis Global Clinical Trials Review, H1, 2012" provides data on the Bronchiectasis clinical...

• Emphysema - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, May 2012 , Pages: 33
  Emphysema – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Emphysema - Pipeline Review, H1 2012', provides an overview of the Emphysema therapeutic pipeline. This report provides information...

• Lung Injury - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, May 2012 , Pages: 81
  Lung Injury – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Lung Injury - Pipeline Review, H1 2012', provides an overview of the Lung Injury therapeutic pipeline. This report provides...

• Pulmonary Fibrosis - Pipeline Review, H1 2012

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, May 2012 , Pages: 58
  Pulmonary Fibrosis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Pulmonary Fibrosis - Pipeline Review, H1 2012', provides an overview of the Pulmonary Fibrosis therapeutic pipeline....